For years, supply chain planning has rewarded precision. The goal was clear: build the most accurate forecast, validate assumptions, and align across the organization before committing to action. Being right was the objective.
In medical device organizations, this mindset runs even deeper. The business is built on safety, traceability, and compliance. Decisions are expected to be well supported, well documented, and thoroughly validated. That discipline is not optional. It is foundational.
But not every decision carries the same level of risk.
That is where the tension begins.
Today’s supply chain environment is not rewarding the most precise plans. It is rewarding the fastest, most effective responses. In many cases, the companies that win are not the ones that are most accurate. They are the ones that act first. This is a critical component of supply chain success in a turbulent, unpredictable state.
For medical device leaders, the challenge is not simply to move faster. It is to understand where speed creates advantage, where rigor must remain, and how to operate differently without compromising what matters most.
There is a cost embedded in many planning organizations that is rarely measured directly. It shows up in delays, missed opportunities, and lost supply, but it is not typically tracked.
This cost is decision latency.
Decision latency is the time between recognizing a need and acting on it. It is the gap between insight and execution, and in many organizations, that gap is growing. Organizations have more data available today than ever before and yet decision making remains slow.
In medical device environments, latency is often amplified by design. Planning teams operate within governance structures that prioritize accuracy and alignment. A potential supply issue is identified, validated, and escalated. Input is gathered from procurement, operations, and quality. If a change is required, it may trigger regulatory considerations such as 510(k) supplements, additional validation, or biocompatibility and EMC review.
Each step is justified. Each step adds time.
Meanwhile, the market continues to move. Suppliers allocate constrained components. Other industries commit earlier and in larger volumes. By the time a decision is finalized, the available supply may already be gone.
The issue is not that these processes exist. The issue is that the same level of rigor is often applied to decisions that do not carry the same level of consequence.
Not all decisions require the same level of certainty, but many are treated as if they do.
Most planning processes were built for a different environment. They were designed around structured cycles, periodic reviews, and a bias toward completeness.
Quarterly S&OP cycles are a clear example. They create alignment, but they also introduce delay. Decisions are often held until the next cycle, even when conditions are changing daily. At the same time, organizations tend to favor additional data over timely action. The instinct is to wait for more information, broader alignment, or greater confidence.
This approach optimizes being right. It does not optimize for being timely.
In stable environments, this tradeoff was acceptable. In today’s environment, it is not.
Supply constraints, cross industry competition for components, and increased demand volatility have changed the equation. The ability to respond quickly is now a defining factor in performance. Decision latency is no longer just an internal inefficiency. It is a competitive disadvantage.
One of the reasons decision latency persists is that its impact is difficult to isolate. It does not show up as a single metric or a clear failure point.
Instead, it appears in downstream effects.
A delayed supplier commitment results in lost allocation. A slow response to a disruption leads to missed production windows. A late decision on a product launch compresses timelines and increases risk across validation and regulatory processes.
Over time, these delays shape how suppliers perceive the organization. Companies that move slowly are seen as less predictable partners. They may be deprioritized in favor of customers who commit earlier and more consistently.
In medical device environments, the consequences can be even more complex. Delays can trigger additional validation requirements, create pressure on regulatory timelines, and introduce rework that could have been avoided with earlier action.
These outcomes are rarely attributed back to decision latency directly, but they are often rooted in it.
“With the continuing disruption and uncertainty, Kinaxis has seen elevated usage of scenario planning, a functionality embedded in our Maestro platform. Scenario modeling provides supply chains with options and corresponding financial impact to support decision making. The ability to quickly run scenarios, moves supply chains from reactive adjustments to proactive, insight-driven responses. Leveraging technology to quickly assess disruptions supports faster decision making, reducing or ideally eliminating decision latency which is key in today’s turbulent environment.” Christy Christian, Kinaxis, Sr. Industry Principal
For many medical device organizations, the challenge is not recognizing the need for faster decisions. It is understanding how to move faster without introducing unacceptable risk.
The answer is not to abandon the discipline that defines the industry. It is to apply it more precisely.
Not all decisions carry the same level of consequence. Regulatory changes, product design decisions, and validation activities must remain deliberate and thorough. They are designed that way for a reason.
Planning decisions are different. Many of them are directional, reversible, and made under uncertainty. Treating them with the same level of rigor as regulated decisions introduces delay without reducing meaningful risk.
Organizations that are improving decision speed are starting by redefining decision types. They are separating what must be fully validated from what can be adjusted over time. Supplier commitments, allocation decisions, and scenario selection are being managed through faster pathways, while strict governance remains in place where it truly matters.
They are also changing how decisions are made. Instead of waiting for sequential alignment across functions, teams are working from a shared view of the problem. Planning, operations, and procurement are evaluating the same scenarios at the same time, reducing the need for multiple handoffs.
This shift does not eliminate collaboration. It makes it more immediate.
Finally, leading organizations are beginning to measure what has historically been invisible. Decision latency is being tracked alongside forecast accuracy, making it clear where delays are occurring and how they impact performance.
The goal is not to move faster at the expense of quality. It is to move faster where speed creates advantage, while preserving rigor where it protects the business.
Process and mindset shifts are critical, but they are difficult to sustain without the right technology.
Many organizations still operate with fragmented systems and delayed data flows. Information is gathered, consolidated, and shared in batches. By the time it is reviewed, it is already outdated. This naturally slows decision making and reinforces the need for additional validation.
Modern planning approaches change this dynamic.
Real time visibility across the supply network allows teams to respond to changes as they happen. Concurrent planning enables demand, supply, and inventory decisions to be evaluated together, rather than in sequence. Scenario simulation allows teams to test options quickly and understand tradeoffs without waiting for extended analysis cycles.
The result is not perfect certainty. It is faster, more informed action.
When teams can evaluate scenarios in minutes instead of weeks, the conversation shifts. Instead of asking whether the data is complete, the focus moves to choosing the best path forward given current conditions.
To improve decision speed, organizations need to rethink how they define success in planning.
